Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4992 - The addition of apatinib to gefitinib or icotinib for advanced non-small cell lung cancer with acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitor: an assessment of effectiveness and safety

Date

09 Sep 2017

Session

Poster display session

Presenters

Chai Ying

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

C. Ying1, Y. Wu2

Author affiliations

  • 1 Thoracic Department, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN
  • 2 Thoracic Department, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310000 - Hangzhou/CN
More

Resources

Abstract 4992

Background

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been proved as an effective treatment of advanced non-small-cell lung cancer patients with EGFR mutations. However, resistance to EGFR-TKIs develops in most patients and leads to eventual loss of efficacy. Nowadays combined therapy inhibiting EGFR and vascular endothelial growth factor (VEGF) pathways has become a promising therapy in the treatment of advanced non-small-cell lung cancer. This study aims to assess the efficacy and safety of the addition of low dose of apatinib, a kind of TKIs targeting vascular endothelial growth factor receptor 2 (VEGFR-2), to first-generation EGFR-TKIs for advanced non-small cell lung cancer with acquired resistance to first-generation EGFR-TKIs.

Methods

We retrospectively assessed the efficacy and safety of patients with non-small cell lung cancer who had gradual progression after experiencing effective targeted therapy with first-generation EGFR-TKIs. Patients received apatinib 250 mg once daily and gefitinib 250mg once daily or icotinib 125mg thrice daily until disease progression again or unacceptable toxicity occurs.

Results

The study group comprised 33 Chinese patients, among whom 15 (45.5%) were males and 20 (60.6%) were non-smokers. The median duration of combined therapy was 5.5 month. 17 patients (51.5%) had a partial response (PR) and 13 patients had stable disease (SD). The overall response rate was 51.5%. 21 cases of adverse events were observed in this study. The incidence of severe adverse events was only 3.0%. The incidence of adverse events in patients decreased in hypertension, rash, proteinuria, hand-foot syndrome, gastrointestinal reaction, mucosal inflammation, bleeding, alanine aminotransferase increased and hypoovarianism.

Conclusions

The addition of low dose of apatinib to gefitinib or icotinib can significantly inhibit tumor growth and improve the progression-free survival of patients received first-generation EGFR-TKIs. Potential advantage in safety were identified which warrant further validation.

Clinical trial identification

Not application

Legal entity responsible for the study

None

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.